Newron’s pivotal Stars study, testing sarizotan in Rett syndrome, was always a high risk bet ? the company lacked any human data on the project before starting the trial. Stars duly missed its primary endpoint, and Newron’s shares have tanked 70% today.
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced today that top-line results from its STARS clinical study evaluating sarizotan in patients with Rett syndrome did not demonstrate evidence of efficacy on the primary or secondary efficacy variables. Consequentially, Newron has decided to terminate this development program.
Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 1 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe, the Juncker plan. Tranche 1 under this financing agreement consists of EUR 10 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system.
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announces that the STARS clinical study (Sarizotan Treatment of Apneas in Rett Syndrome) in patients with Rett syndrome is expected to complete enrollment in H2 2018. Newron expects to report results from the STARS study in H1 2019.
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Bo Jesper Hansen has informed the Board of Directors of his intention to step down as a Non-Executive Director, effective from this year’s Annual Shareholders Assembly taking place on March 27, 2018.